Detalles de la búsqueda
1.
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.
Blood
; 138(21): 2031-2041, 2021 11 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-34407542
2.
Treatment patterns and outcomes for Hodgkin Lymphoma patients aged 60 and older: a report from the Brazilian Prospective Hodgkin Lymphoma Registry.
Ann Hematol
; 102(10): 2815-2822, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37474632
3.
Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study.
Ann Intern Med
; 168(7): 461-470, 2018 04 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29459949
4.
Lower socioeconomic status is independently associated with shorter survival in Hodgkin Lymphoma patients-An analysis from the Brazilian Hodgkin Lymphoma Registry.
Int J Cancer
; 142(5): 883-890, 2018 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29023692
5.
Treatment outcomes for Hodgkin lymphoma: First report from the Brazilian Prospective Registry.
Hematol Oncol
; 36(1): 189-195, 2018 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-28643458
6.
BCR-ABL Mutations in Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors and Impact on Survival.
Cancer Invest
; 2015 Aug 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-26279306
7.
BCR-ABL mutations in chronic myeloid leukemia treated with tyrosine kinase inhibitors and impact on survival.
Cancer Invest
; 33(9): 451-8, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26288116
8.
Vox Sanguinis International Forum on Hospital Transfusion Services' Response to COVID-19: Responses.
Vox Sang
; 115(6): e1-e17, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32403155
9.
Vox Sanguinis International Forum on transfusion services' response to COVID-19: Summary.
Vox Sang
; 115(6): 536-542, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32384164
10.
Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors.
J Cancer Res Clin Oncol
; 149(9): 6247-6262, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-36707445
11.
Health-related quality of life of patients with resistant/intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trial.
Leukemia
; 37(5): 1060-1067, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37069326
12.
Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL.
Leukemia
; 37(3): 617-626, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36717654
13.
Brazilian chronic myeloid leukemia working group recommendations for discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia in clinical practice.
Hematol Transfus Cell Ther
; 44(3): 402-409, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35654721
14.
Inclusion of molecular monitoring (BCR-ABL1) in the treatment of chronic myeloid leukemia in the Brazilian Public Health System (SUS): an urgent need for treatment management.
Hematol Transfus Cell Ther
; 43(1): 50-57, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-32475788
15.
Treatment-free remission in patients with chronic myeloid leukemia: recommendations of the LALNET expert panel.
Blood Adv
; 5(23): 4855-4863, 2021 12 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-34438444
16.
Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis.
Leukemia
; 35(2): 440-453, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33414482
17.
COVID-19 in chronic myeloid leukemia patients in Latin America.
Leuk Lymphoma
; 62(13): 3212-3218, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34254886
18.
Effect of Convalescent Plasma in Critically Ill Patients With COVID-19: An Observational Study.
Front Med (Lausanne)
; 8: 630982, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33585529
19.
Treatment outcomes in classic Hodgkin lymphoma: 5-year update from the Brazilian Hodgkin Lymphoma Registry.
EJHaem
; 4(4): 1191-1195, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-38024602
20.
Brazilian chronic myeloid leukemia working group recommendations for discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia in clinical practice
Hematol., Transfus. Cell Ther. (Impr.)
; 44(3): 402-409, July-Sept. 2022. tab, ilus
Artículo
en Inglés
| LILACS | ID: biblio-1405002